Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107).

Trial Profile

Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107).

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Asenapine (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Acronyms Gemini-BP3
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Dec 2015 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry
    • 13 Mar 2015 According to an Actavis media release, based on the results of this trial US FDA has approved its sNDA for asenapine [SAPHRIS] as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients.
    • 02 Oct 2013 The status of the extension study has changed from recruiting to active, no longer recruiting, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top